Celldex Therapeutics SVPs Engage in Not-So-Great Transactions

So, here we are-Freddy A. Jimenez, Senior Vice President & General Counsel of Celldex Therapeutics (CLDX 5.22%) decides to shake things up a bit on December 4, 2025, by selling 4,166 shares on the open market. I mean, who doesn’t love a little insider trading? Just kidding! It’s totally legal, but still, let’s keep our eyebrows raised, shall we?

buying this stock now is about as wise as ordering the fish special at a questionable diner.

Advertisement

Glossary

Open-market sale: Selling securities on a public exchange at market prices.
Form 4: An SEC filing disclosing insider trades by corporate bigwigs.
Direct ownership: Shares held personally-not through some convoluted family trust.
Indirect holdings: Shares owned through entities like trusts or family members, for those who like to complicate things unnecessarily.
Derivative securities: Financial contracts based on underlying assets, because why do anything the easy way?
Disposition: Selling or transferring ownership of an asset.
Cadence: The rhythm of insider share sales-think of it like a dance, only less fun.
Capacity-driven: A transaction driven by available shares, not intent.
Monoclonal antibodies: Engineered molecules targeting specific cells-like a precision laser for your immune system.
Bispecific antibodies: Designed to bind two different targets at once, because apparently one isn’t enough.
Clinical-stage: Refers to a company in the human testing phase of drug development.
TTM: The last 12 months, ending with the most recent quarterly report.

So there you have it-investing in Celldex right now feels like going to a party you were never invited to. You show up, and suddenly everyone’s awkwardly looking around, trying to figure out who brought the weird dip. 🧐

Read More

2026-01-12 18:42